Fate Therapeutics, Inc.FATENASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank79
5Y CAGR-23.7%
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

5Y CAGR
-23.7%/yr
Long-term compound
Percentile
P79
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
202513.66%
20247.10%
202346.71%
2022-52.40%
2021-315.18%
202052.84%
2019-115.20%
2018-4.73%
2017-23.75%
2016-62.11%